Research Reference
Tesamorelin
FDA-approved GHRH analog for HIV-associated lipodystrophy
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Tesamorelin (Egrifta) is an FDA-approved growth hormone-releasing hormone (GHRH) analog indicated for HIV-associated lipodystrophy.
Dosing Reference
Reconstitution
Add 2 mL bacteriostatic water to the 2 mg vial. Resulting concentration: 1 mg/mL.
| Dose | Syringe Units | mL Volume | Schedule |
|---|---|---|---|
| 2 mg | 200 units | 2 mL | SubQ, once dailyFDA-approved dose (Egrifta) |
Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before use. Round half-units to the nearest visible mark.
Reconstitution
Tesamorelin (Egrifta) is FDA-approved for HIV-associated lipodystrophy and is supplied as a lyophilized 2 mg vial reconstituted with 2 mL sterile water for a 1 mg/mL concentration. Compounded research-peptide forms are not FDA-approved.
For a 2 mg vial reconstituted with 2 mL, the concentration is 1 mg/mL; a 2 mg dose draws to 200 units (2 mL) — the full vial — on a U-100 syringe. Reconstitute per manufacturer directions; use promptly and store refrigerated.
Cycling Protocol
FDA-approved tesamorelin is 2 mg subcutaneously once daily as chronic therapy for HIV-associated visceral fat accumulation. No fixed cycle end; used long-term. Discontinuation is by clinical decision.
Routes of Administration
Subcutaneous injection (only established route): Once daily into the abdomen. Best given on an empty stomach at bedtime to minimize GH-related effects.
No oral, intranasal, or intravenous route is established. Compounded forms are not FDA-approved.
Stacking Protocols
| Stack | Components | Purpose | | --- | --- | --- | | GHRH + Lifestyle | Tesamorelin + diet/exercise | FDA-approved lipodystrophy protocol |
Combining with other GH secretagogues is not established. Compounded forms are not FDA-approved.
Side Effects & Safety
- Injection-site reactions — redness, itching, bruising (most common)
- Nausea, headache, fatigue — common
- Musculoskeletal pain, joint pain — common
- Lipodystrophy worsening at injection sites — rotate sites
- Hypersensitivity — rare
Tesamorelin (Egrfta) is FDA-approved for HIV-associated lipodystrophy. Compounded research-peptide forms are not FDA-approved.
Research Basis
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), with a stabilized sequence extending half-life.
Mechanism: Stimulates the pituitary to release endogenous growth hormone in a pulsatile, physiologic manner — increasing IGF-1 and mobilizing visceral adipose tissue.
Clinical evidence: FDA-approved (Egrfta, 2010) to reduce excess visceral abdominal fat in HIV-associated lipodystrophy. Demonstrated reductions in visceral adipose tissue and triglycerides.
FDA-approved for HIV-associated lipodystrophy. Compounded research-peptide forms are not FDA-approved.